38996764|t|Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an amyotrophic lateral sclerosis mouse model.
38996764|a|BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons. The limited efficacy of recent therapies in clinical development may be linked to lack of drug penetration to the affected motor neurons due to the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB). METHODS: In this work, the safety and efficacy of repeated short transient opening of the BSCB by low intensity pulsed ultrasound (US, sonication) was studied in females of an ALS mouse model (B6.Cg-Tg(SOD1*G93A)1Gur/J). The BSCB was disrupted using a 1 MHz ultrasound transducer coupled to the spinal cord, with and without injection of insulin-like growth factor 1 (IGF1), a neurotrophic factor that has previously shown efficacy in ALS models. FINDINGS: Results in wild-type (WT) animals demonstrated that the BSCB can be safely disrupted and IGF1 concentrations significantly enhanced after a single session of transient BSCB disruption (176 +- 32 mug/g vs. 0.16 +- 0.008 mug/g, p < 0.0001). Five repeated weekly US sessions performed in female ALS mice demonstrated a survival advantage in mice treated with IGF1 and US (US IGF1) compared to treatment with IGF1 alone (176 vs. 166 days, p = 0.0038). Surprisingly, this survival advantage was also present in mice treated with US alone vs. untreated mice (178.5 vs. 166.5 days, p = 0.0061). Muscle strength did not show difference among the groups. Analysis of glial cell immunoreactivity and microglial transcriptome showing reduced cell proliferation pathways, in addition to lymphocyte infiltration, suggested that the beneficial effect of US or US IGF1 could act through immune cell modulation. INTERPRETATION: These results show the first step towards a possible beneficial impact of transient BSCB opening for ALS therapy and suggest implication of immune cells. FUNDING: Fondation pour la Recherche Medicale (FRM). Investissements d'avenirANR-10-IAIHU-06, Societe Francaise de Neurochirurgie (SFNC), Fond d'etude et de Recherche du Corps Medical (FERCM), Aide a la Recherche des Maladies du Cerveau (ARMC), SLA Fondation Recherche (SLAFR), French Ministry for High Education and Research (MENR), Carthera, Laboratoire de Recherche en Technologies Chirurgicales Avancees (LRTCA).
38996764	112	141	amyotrophic lateral sclerosis	Disease	MESH:D000690
38996764	142	147	mouse	Species	10090
38996764	167	196	Amyotrophic lateral sclerosis	Disease	MESH:D000690
38996764	198	201	ALS	Disease	MESH:D000690
38996764	214	239	neurodegenerative disease	Disease	MESH:D019636
38996764	682	685	ALS	Disease	MESH:D000690
38996764	686	691	mouse	Species	10090
38996764	699	704	B6.Cg	CellLine	CVCL:C6EU
38996764	713	717	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:16000;CorrespondingGene:3479;RS#:745805222;CorrespondingSpecies:10090;CA#:242663201
38996764	844	872	insulin-like growth factor 1	Gene	16000
38996764	874	878	IGF1	Gene	16000
38996764	941	944	ALS	Disease	MESH:D000690
38996764	1052	1056	IGF1	Gene	16000
38996764	1255	1258	ALS	Disease	MESH:D000690
38996764	1259	1263	mice	Species	10090
38996764	1301	1305	mice	Species	10090
38996764	1319	1323	IGF1	Gene	16000
38996764	1335	1339	IGF1	Gene	16000
38996764	1368	1372	IGF1	Gene	16000
38996764	1469	1473	mice	Species	10090
38996764	1510	1514	mice	Species	10090
38996764	1812	1816	IGF1	Gene	16000
38996764	1976	1979	ALS	Disease	MESH:D000690

